Know Cancer

forgot password

Thoracoscopic Internal Mammary Sentinel Node Biopsy

18 Years
Not Enrolling
Breast Cancer

Thank you

Trial Information

Thoracoscopic Internal Mammary Sentinel Node Biopsy


- Determine the occurrence rate of internal mammary sentinel lymph nodes in patients with
medially or centrally located stage I or II breast cancer.

- Determine the safety, feasibility, and success rate of thorascopic internal mammary
sentinel lymph node biopsy in these patients.

- Determine the rate of metastatic disease in internal mammary sentinel lymph nodes
obtained thoracoscopically in these patients.

OUTLINE: Patients undergo standard axillary sentinel lymph node dissection during surgery
(i.e., lumpectomy or mastectomy). Patients receive a radioactive tracer (i.e., technetium Tc
99m sulfur colloid) and isosulfan blue by peritumoral injection for identification of the
axillary and internal mammary sentinel lymph nodes (IMSLN). Identified axillary sentinel
lymph nodes are dissected. Identified IMSLNs are removed through the lumpectomy/mastectomy
incision, if accessible. If they are not accessible, patients undergo thorascopic IMSLN
biopsy to remove the nodes.

All removed sentinel lymph nodes (axillary or internal mammary) are examined for gross and
microscopic carcinoma for future therapy planning.

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.

Inclusion Criteria


- Histologically confirmed breast cancer

- Stage I or II disease (T1-T2, N0, M0/MX disease)

- No chest wall invasion by tumor (T3 disease)

- Medially or centrally located lesion

- No multicentric disease

- Multifocal disease allowed

- No clinically positive axillary nodes

- No enlarged internal mammary nodes by CT scan

- Hormone receptor status not specified


- Male or female

- Menopausal status not specified

- American Society of Anesthesiologists (ASA) physical status classification 1-2

- Not pregnant or nursing

- Negative pregnancy test

- No other concurrent known, invasive malignancy

- No known chronic pulmonary disease

- No known allergy to methylene blue or isosulfan blue


- No prior thoracic or cardiac surgery

- No prior ipsilateral chest tube placement

- Contralateral chest tube placement allowed

- No prior neoadjuvant chemotherapy

- No prior radiotherapy to the mediastinum

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy

Outcome Time Frame:

5 years

Safety Issue:


Principal Investigator

Eli Avisar, MD

Investigator Role:

Study Chair

Investigator Affiliation:

University of Miami Sylvester Comprehensive Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

May 2004

Completion Date:

March 2011

Related Keywords:

  • Breast Cancer
  • stage I breast cancer
  • stage II breast cancer
  • male breast cancer
  • Breast Neoplasms



University of Miami Sylvester Comprehensive Cancer Center - MiamiMiami, Florida  33136